CANCER:

Mast Cell Leukemia

News alerts, weekly reports and conference planners

TMB-L	Mast Cell Leukemia	TMB-L	Mast Cell Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
LDH-L	Mast Cell Leukemia	LDH-L	Mast Cell Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
KIT D816V	Mast Cell Leukemia	KIT D816V	Mast Cell Leukemia	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D
KIT D816V	Mast Cell Leukemia	KIT D816V	Mast Cell Leukemia	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
KIT D816V	Mast Cell Leukemia	KIT D816V	Mast Cell Leukemia	ribociclib Sensitive: D – Preclinical ribociclib Sensitive : D	ribociclib Sensitive: D – Preclinical ribociclib Sensitive : D

Associations(5)